Results 161 to 170 of about 15,553 (191)
Some of the next articles are maybe not open access.
Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study [PDF]
Lancet Infectious Diseases, The, 2016 Background Carbapenems are frequently the last line of defence in serious infections due to multidrug-resistant Gram-negative bacteria, but their use is threatened by the growing prevalence of carbapenemase-producing pathogens.
Yehuda Carmeli, Gregory G Stone
exaly +3 more sources